Unicycive Therapeutics (UNCY) News Today $0.62 +0.01 (+0.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 25.4% in DecemberUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,240,000 shares, a growth of 25.4% from the December 15th total of 989,200 shares. Currently, 1.4% of the company's shares are short sold. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 0.8 days.January 16, 2025 | marketbeat.comUnicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC WainwrightJanuary 11, 2025 | americanbankingnews.comUnicycive Therapeutics Receives Notice of Non-Compliance from NasdaqJanuary 10, 2025 | americanbankingnews.comPositive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue ForecastsJanuary 9, 2025 | markets.businessinsider.comUnicycive Therapeutics (NASDAQ:UNCY) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Unicycive Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comUnicycive Therapeutics announces publication of OLC dose escalation dataJanuary 8, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational ScienceJanuary 7, 2025 | globenewswire.comUnicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical TherapeuticsDecember 17, 2024 | markets.businessinsider.comShort Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Drops By 33.6%Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 837,200 shares, a drop of 33.6% from the November 15th total of 1,260,000 shares. Based on an average daily trading volume, of 1,610,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.0% of the company's stock are sold short.December 13, 2024 | marketbeat.comWalleye Capital LLC Invests $2.04 Million in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,000,000 shares of the company's stock, vDecember 4, 2024 | marketbeat.comBreakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)November 28, 2024 | uk.finance.yahoo.comAcuta Capital Partners LLC Purchases Shares of 1,979,199 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Acuta Capital Partners LLC acquired a new position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,979,199 shares of the company's stock, valued at approximately $807,000. Unicycive TherapeutNovember 28, 2024 | marketbeat.comGreat Point Partners LLC Buys Shares of 8,559,000 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,559,000 shares of the company's stock, valued at approximately $3,491,0November 27, 2024 | marketbeat.comBenchmark Reiterates Speculative Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)Benchmark reiterated a "speculative buy" rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday.November 22, 2024 | marketbeat.comUnicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare ConferenceNovember 21, 2024 | globenewswire.comUnicycive Therapeutics price target raised to $4 from $2.50 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comUnicycive Therapeutics (UNCY) Gets a Buy from Noble FinancialNovember 15, 2024 | markets.businessinsider.comUnicycive Therapeutics expects cash to fund operations into 2026November 14, 2024 | markets.businessinsider.comUnicycive Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | globenewswire.comUnicycive Therapeutics announces U.S. FDA acceptane for NDA for OLCNovember 13, 2024 | markets.businessinsider.comPositive Buy Rating for Unicycive Therapeutics Driven by NDA Acceptance and Strong Market Potential for Oxylanthanum CarbonateNovember 13, 2024 | markets.businessinsider.comUnicycive: FDA to Review Lead Drug Candidate for HyperphosphatemiaNovember 11, 2024 | marketwatch.comUnicycive Says FDA Accepts NDA For Oxylanthanum Carbonate To Treat Patients With CKD On DialysisNovember 11, 2024 | markets.businessinsider.comUnicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisNovember 11, 2024 | globenewswire.comUnicycive presents on development progress of oxylanthanum carbonateOctober 28, 2024 | markets.businessinsider.comUnicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024October 28, 2024 | globenewswire.comRubius Therapeutics Inc Com (OTC:RUBY) Stock Quotes, Forecast and News SummaryOctober 20, 2024 | benzinga.comUnicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024October 16, 2024 | globenewswire.comUnicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024October 14, 2024 | globenewswire.comUnicycive Therapeutics: A Buy Rating with a $2.50 Price Target Amid Clinical and Regulatory AdvancesOctober 10, 2024 | markets.businessinsider.comUnicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy VolunteersOctober 9, 2024 | globenewswire.comUnicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024September 24, 2024 | globenewswire.comUnicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024September 16, 2024 | globenewswire.comBuy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong Financial OutlookSeptember 7, 2024 | markets.businessinsider.comUnicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comUnicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisSeptember 3, 2024 | globenewswire.comUnicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024August 26, 2024 | globenewswire.comCompanies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In GrowthAugust 21, 2024 | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 15, 2024 | finanznachrichten.deIndia's SpiceJet reports drop in Q1 profit on fewer flightsAugust 15, 2024 | uk.finance.yahoo.comUNCY Stock Earnings: Unicycive Therapeutics Beats EPS for Q2 2024August 14, 2024 | investorplace.comUnicycive Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comUNCY Unicycive Therapeutics, Inc.July 20, 2024 | seekingalpha.comUnicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)July 17, 2024 | globenewswire.comUnicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceJuly 11, 2024 | globenewswire.comUnicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)July 10, 2024 | globenewswire.comUnicycive Therapeutics Joins Russell Microcap® IndexJuly 1, 2024 | globenewswire.comBuy Rating Affirmed on Unicycive Therapeutics Amid Promising Kidney Treatment AdvancesMay 29, 2024 | markets.businessinsider.comUnicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association CongressMay 28, 2024 | globenewswire.comUnicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceMay 23, 2024 | globenewswire.com Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address UNCY Media Mentions By Week UNCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼0.480.44▲Average Medical News Sentiment UNCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼11▲UNCY Articles Average Week Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies iTeos Therapeutics News Y-mAbs Therapeutics News Aquestive Therapeutics News Immutep News Olema Pharmaceuticals News Atyr PHARMA News Rezolute News Neurogene News Compass Therapeutics News Atea Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts